The C3 Gene Therapy Initiative seeks to accelerate the understanding of gene therapy as a treatment for LGMD2A/calpainopathy by funding the research of multiple gene therapy approaches. If results from any current or future Gene Therapy Initiative research projects are positive, they can be progressed towards the initiation of clinical trials for LGMD2A patients. Bringing a therapy from the research lab to a clinical trial is a long and expensive process. C3 is currently funding early stage projects to answer critical questions about effectiveness and safety, which must be established before gene therapy can be tested in patients. In addition to gene therapy, C3 will continue to explore and fund other approaches that could lead to therapies that can slow the progression of the disease or cure LGMD2A. One hundred percent of donations made to this fundraiser will be put to work to fund gene therapy scientific research focused on LGMD2A/calpainopathy.